EMN 2021 | FORTE: MRD negativity as key prognostic factor in NDMM
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, shares an update from the FORTE trial (NCT02203643), focusing on measurable residual disease (MRD) results as assessed by multiparameter flow cytometry (MFC) and next generation sequencing (NGS) in patients with newly diagnosed transplant-eligible multiple myeloma (NDMM). Analysis with both MFC and NGS found that conversion of MRD positivity to MRD negativity was high in patients receiving carfilzomib plus lenalidomide (KR) maintenance therapy. MFC and NGS both demonstrated similar outcomes, confirming a high concordance between these two techniques. The study found that patients who received KR achieved a significantly longer progression-free survival (PFS) versus those who received lenalidomide alone, even in patients who were MRD-negative before maintenance therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Alessandro Gozzetti, MD, PhD, has received research funding from Janssen and Cilag Spa.
